Literature DB >> 25963090

Gastrointestinal cancer: Rationale for metronomic chemotherapy in phase III trials.

Robert S Kerbel1, Axel Grothey2.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25963090     DOI： 10.1038/nrclinonc.2015.89

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

Review 1.  Metronomic chemotherapy: new rationale for new directions.

Authors:  Eddy Pasquier; Maria Kavallaris; Nicolas André
Journal:  Nat Rev Clin Oncol       Date:  2010-06-08       Impact factor: 66.675

2.  Why do phase III clinical trials in oncology fail so often?

Authors:  Laleh Amiri-Kordestani; Tito Fojo
Journal:  J Natl Cancer Inst       Date:  2012-04-06       Impact factor: 13.506

3.  Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.

Authors:  David Cunningham; Istvan Lang; Eugenio Marcuello; Vito Lorusso; Janja Ocvirk; Dong Bok Shin; Derek Jonker; Stuart Osborne; Niko Andre; Daniel Waterkamp; Mark P Saunders
Journal:  Lancet Oncol       Date:  2013-09-10       Impact factor: 41.316

Review 4.  Colorectal cancer in 2014: progress in defining first-line and maintenance therapies.

Authors:  Joleen M Hubbard; Axel Grothey
Journal:  Nat Rev Clin Oncol       Date:  2015-01-06       Impact factor: 66.675

5.  Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.

Authors:  G Klement; S Baruchel; J Rak; S Man; K Clark; D J Hicklin; P Bohlen; R S Kerbel
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

6.  Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.

Authors:  Joseph Gligorov; Dinesh Doval; José Bines; Emilio Alba; Paulo Cortes; Jean-Yves Pierga; Vineet Gupta; Rômulo Costa; Stefanie Srock; Sabine de Ducla; Ulrich Freudensprung; Giorgio Mustacchi
Journal:  Lancet Oncol       Date:  2014-09-28       Impact factor: 41.316

7.  Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.

Authors:  Lieke H J Simkens; Harm van Tinteren; Anne May; Albert J ten Tije; Geert-Jan M Creemers; Olaf J L Loosveld; Felix E de Jongh; Frans L G Erdkamp; Zoran Erjavec; Adelheid M E van der Torren; Jolien Tol; Hans J J Braun; Peter Nieboer; Jacobus J M van der Hoeven; Janny G Haasjes; Rob L H Jansen; Jaap Wals; Annemieke Cats; Veerle A Derleyn; Aafke H Honkoop; Linda Mol; Cornelis J A Punt; Miriam Koopman
Journal:  Lancet       Date:  2015-04-07       Impact factor: 79.321

Review 8.  Mouse models of advanced spontaneous metastasis for experimental therapeutics.

Authors:  Giulio Francia; William Cruz-Munoz; Shan Man; Ping Xu; Robert S Kerbel
Journal:  Nat Rev Cancer       Date:  2011-02       Impact factor: 60.716

9.  A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

Authors:  Kristian Pietras; Douglas Hanahan
Journal:  J Clin Oncol       Date:  2004-11-22       Impact factor: 44.544

10.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.

Authors:  T Browder; C E Butterfield; B M Kräling; B Shi; B Marshall; M S O'Reilly; J Folkman
Journal:  Cancer Res       Date:  2000-04-01       Impact factor: 12.701
  10 in total
  13 in total

Review 1.  Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect.

Authors:  Guido Bocci; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2016-05-17       Impact factor: 66.675

2.  Metronomic paclitaxel improves the efficacy of PD-1 monoclonal antibodies in breast cancer by transforming the tumor immune microenvironment.

Authors:  Qian Chen; Rui Xia; Weiwei Zheng; Luyao Zhang; Ping Li; Xingwei Sun; Jianming Shi
Journal:  Am J Transl Res       Date:  2020-02-15       Impact factor: 4.060

Review 3.  Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects.

Authors:  Yuval Shaked
Journal:  Nat Rev Clin Oncol       Date:  2016-04-26       Impact factor: 66.675

4.  Role of vascular normalization in benefit from metronomic chemotherapy.

Authors:  Fotios Mpekris; James W Baish; Triantafyllos Stylianopoulos; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-07       Impact factor: 11.205

5.  Development of Patient Derived Xenograft Models of Overt Spontaneous Breast Cancer Metastasis: A Cautionary Note.

Authors:  Marta Paez-Ribes; Shan Man; Ping Xu; Robert S Kerbel
Journal:  PLoS One       Date:  2016-06-29       Impact factor: 3.240

6.  Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells.

Authors:  Tze-Sian Chan; Chung-Chi Hsu; Vincent C Pai; Wen-Ying Liao; Shenq-Shyang Huang; Kok-Tong Tan; Chia-Jui Yen; Shu-Ching Hsu; Wei-Yu Chen; Yan-Shen Shan; Chi-Rong Li; Michael T Lee; Kuan-Ying Jiang; Jui-Mei Chu; Gi-Shih Lien; Valerie M Weaver; Kelvin K Tsai
Journal:  J Exp Med       Date:  2016-11-23       Impact factor: 14.307

Review 7.  Therapy-activated stromal cells can dictate tumor fate.

Authors:  Robert S Kerbel; Yuval Shaked
Journal:  J Exp Med       Date:  2016-11-23       Impact factor: 14.307

8.  Nanometronomic treatment of 4T1 breast cancer with nanocaged doxorubicin prevents drug resistance and circumvents cardiotoxicity.

Authors:  Serena Mazzucchelli; Michela Bellini; Luisa Fiandra; Marta Truffi; Maria A Rizzuto; Luca Sorrentino; Erika Longhi; Manuela Nebuloni; Davide Prosperi; Fabio Corsi
Journal:  Oncotarget       Date:  2017-01-31

Review 9.  Trends and Challenges in Tumor Anti-Angiogenic Therapies.

Authors:  József Jászai; Mirko H H Schmidt
Journal:  Cells       Date:  2019-09-18       Impact factor: 6.600

10.  Metronomic chemotherapy offsets HIFα induction upon maximum-tolerated dose in metastatic cancers.

Authors:  Luana Schito; Sergio Rey; Ping Xu; Shan Man; William Cruz-Muñoz; Robert S Kerbel
Journal:  EMBO Mol Med       Date:  2020-07-20       Impact factor: 12.137
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.